Carregant...

Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval

There has been a dearth of new drugs approved for cardiovascular disorders. The cost is prohibitive, averaging to $2.5 billion, and requiring 12.5 years. This is in large part due to the high failure rate, with only 5% approval by the Food and Drug Administration. Despite preclinical studies showing...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JACC Basic Transl Sci
Autor principal: Roberts, Robert
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6234613/
https://ncbi.nlm.nih.gov/pubmed/30456340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacbts.2018.08.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!